Serum HMGB1 levels reflect tumor cell lysis and ICD-driven DC activation, whereas CXCL9/CXCL10 gradients predict Batf3-dependent CD103+ DC migration and T-cell priming [63, 113, 114]. Here, CXCL9 is linked to neoplasm.